PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 41, issue 12, 2023

The Carer QALY Trap and Altruism in Economic Evaluations pp. 1553-1555

J. Mick Tilford and Aygul Tarlan

Modelling Spillover Effects on Informal Carers: The Carer QALY Trap pp. 1557-1561

David J. Mott, Hannah Schirrmacher, Hareth Al-Janabi, Sophie Guest, Becky Pennington, Nicolas Scheuer, Koonal K. Shah and Chris Skedgel

Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies pp. 1563-1588

Deborah A. Marshall, Brittany Gerber, Diane L. Lorenzetti, Karen V. MacDonald, Riley Jewel Bohach and Gillian R. Currie

Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations pp. 1589-1601

Kumar Mukherjee, Necdet B. Gunsoy, Rita M. Kristy, Joseph C. Cappelleri, Jessica Roydhouse, Judith J. Stephenson, David Vanness, Sujith Ramachandran, Nneka C. Onwudiwe, Sri Ram Pentakota, Helene Karcher and Gian Luca Di Tanna

Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens pp. 1603-1615

David Teigen, Robert O. Opoka, Phillip Kasirye, Catherine Nabaggala, Heather A. Hume, Bjørn Blomberg, Chandy C. John, Russell E. Ware and Bjarne Robberstad

Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework pp. 1617-1627

Boshen Jiao

De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation pp. 1629-1639

Peter Gal, Gyorgyi Feldmajer, Margarida Augusto, Ray Gani, Emma Hook, Ash Bullement, Zoe Philips and Inger Smith

Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland pp. 1641-1655

Michaela Carla Barbier, Alicia Fengler, Esther Pardo, Arjun Bhadhuri, Niklaus Meier and Oliver Gautschi

Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom pp. 1657-1673

Jason Gordon, Maria Gheorghe, Simon Goldenberg, Ryan Miller, James Dennis and Amer Al-Taie

Volume 41, issue 11, 2023

Conducting Trial-Based Economic Evaluations Using R: A Tutorial pp. 1403-1413

Ângela Jornada Ben, Johanna M. Dongen, Mohamed El Alili, Jonas L. Esser, Hana Marie Broulíková and Judith E. Bosmans

Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review pp. 1415-1435

Katja C. Heinz, Charlotte Beaudart, Damon Willems, Isabell Wiethoff and Mickaël Hiligsmann

Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC) pp. 1437-1452

Nick Jovanoski, Seye Abogunrin, Danilo Di Maio, Rossella Belleli, Pollyanna Hudson, Sneha Bhadti and Libby G. Jones

Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies pp. 1453-1467

Xuejing Jin, Wanxian Liang, Lining Zhang, Shihuan Cao, Lujia Yang and Feng Xie

A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus pp. 1469-1514

Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard and Lars Holger Ehlers

EQ-5D-5L Value Set for Slovenia pp. 1515-1524

Valentina Prevolnik Rupel and Marko Ogorevc

Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia pp. 1525-1537

Preston Ngo, Deme Karikios, David Goldsbury, Stephen Wade, Zarnie Lwin, Brett G. M. Hughes, Kwun M. Fong, Karen Canfell and Marianne Weber

Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model pp. 1539-1550

Kathrin Pahmeier, Christian Speckemeier, Silke Neusser, Jürgen Wasem and Janine Biermann-Stallwitz

Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1551-1551

Thomas Otten, Rob Riemsma, Ben Wijnen, Nigel Armstrong, Lisa Stirk, Caroline Gordon, Bram Ramaekers, Jos Kleijnen, Manuela Joore and Sabine Grimm

Volume 41, issue 10, 2023

Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How? pp. 1165-1174

Nancy J. Devlin, Tianxin Pan, Mark Sculpher, Mark Jit, Elly Stolk, Donna Rowen, Barend Hout and Richard Norman

An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year pp. 1175-1182

Jonathan D. Campbell, Melanie D. Whittington and Steven D. Pearson

Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review pp. 1183-1203

Martijn J. Oude Wolcherink, Carina M. Behr, Xavier G. L. V. Pouwels, Carine J. M. Doggen and Hendrik Koffijberg

Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review pp. 1205-1228

Judith Dams, Johann-Jacob Zapp and Hans-Helmut König

Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review pp. 1229-1248

Mussab Fagery, Hadi A. Khorshidi, Stephen Q. Wong, Martin Vu and Maarten IJzerman

Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry pp. 1249-1262

Xinyu Li, Rudolf Hoogenveen, Mohamed El Alili, Saskia Knies, Junfeng Wang, Joline W. J. Beulens, Petra J. M. Elders, Giel Nijpels, Anoukh Giessen and Talitha L. Feenstra

Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients pp. 1263-1274

Xinyu Wang, Kentaro Yamato, Yoshitsugu Kojima, Josef J. Paris, Elisabeth F. P. Peterse, Martijn J. H. G. Simons and Craig Bennison

Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses pp. 1275-1286

Noga Epstein, Tzahit Simon-Tuval and Yakir Berchenko

Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA pp. 1287-1388

Michael Falk Hvidberg and Monica Hernandez Alava

Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries pp. 1389-1402

Sebastian Neumann-Böhme, Iryna Sabat, Carolin Brinkmann, Arthur Attema, Tom Stargardt, Jonas Schreyögg and Werner Brouwer

Volume 41, issue 9, 2023

Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs pp. 1027-1030

Werner Brouwer and Pieter Baal

Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review pp. 1031-1050

Marieke Krol, Nikkie Hosseinnia, Werner Brouwer and Leona Hakkaart Roijen

Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics pp. 1051-1064

Beata Koń and Michał Jakubczyk

Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis pp. 1065-1077

Boshen Jiao and Anirban Basu

Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in Norway pp. 1079-1091

Johan A. Liseth Hansen, Thomas Fast and Knut Wangen

Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries pp. 1093-1101

Paul Hanly, Marta Ortega Ortega, Alison Pearce, Marianna Camargo Cancela, Isabelle Soerjomataram and Linda Sharp

Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects pp. 1103-1115

Werner Brouwer, Kaya Verbooy, Renske Hoefman and Job Exel

Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort pp. 1117-1136

Syed Afroz Keramat, Rubayyat Hashmi, Bolaji Samson Aregbeshola and Tracy Comans

Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses pp. 1137-1149

Saskia Groot, Irene Santi, Pieter Bakx, Bram Wouterse and Pieter Baal

Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy pp. 1151-1164

David D. Kim

Volume 41, issue 8, 2023

Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey pp. 843-844

Alper Tuna Güven

How Much Better is Faster? Value Adjustments for Health-Improvement Sequences pp. 845-856

F. Reed Johnson, Juan Marcos Gonzalez, John J. Sheehan and Shelby D. Reed

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 857-867

Willem Witlox, Sabine Grimm, Jeremy Howick, Nigel Armstrong, Charlotte Ahmadu, Kevin McDermott, Thomas Otten, Caro Noake, Robert Wolff and Manuela Joore

Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review pp. 869-911

Hans Van Remoortel, Hans Scheers, Bert Avau, Jørgen Georgsen, Susan Nahirniak, Nadine Shehata, Simon J. Stanworth, Emmy De Buck, Veerle Compernolle and Philippe Vandekerckhove

Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review pp. 913-943

Charles Okafor, Joshua Byrnes, Simon Stewart, Paul Scuffham and Clifford Afoakwah

A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) pp. 945-980

Lara Chayab, Natalia Konstantelos, Natasha B. Leighl, Mina Tadrous and William W. L. Wong

Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer pp. 981-997

Marianne Luyendijk, Agnes Jager, Sanne M. Buijs, Sabine Siesling, Carin A. Uyl- de Groot and Hedwig M. Blommestein

Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study) pp. 999-1010

Maria Jesus Rodríguez-Nieto, Esteban Cano-Jiménez, Ana D. Romero Ortiz, Ana Villar, Marta Morros, Alba Ramon and Silvia Armengol

Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers pp. 1011-1025

Aurelie Meunier, Louise Longworth, Manuel Gomes, Sreeram Ramagopalan, Louis P. Garrison and Sanjay Popat

Volume 41, issue 7, 2023

Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance pp. 733-740

Stephanie Harvard and Eric Winsberg

Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 741-750

Giovany Orozco Leal, Nigel Armstrong, Ashleigh Kernohan, Charlotte Ahmadu, Diarmuid Coughlan, Kevin McDermott, Steven Duffy, Susan O’Meara, Tomos Robinson, Luke Vale and Jos Kleijnen

Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature pp. 751-769

Daniel D. Joyce, Vidit Sharma and Stephen B. Williams

Economic Impact of Insufficient and Disturbed Sleep in the Workplace pp. 771-785

Danielle R. Glick, Samuel A. Abariga, Irine Thomas, Andrea G. Shipper, Brian C. Gunia, Michael A. Grandner, Elliot Rosenberg, Stella E. Hines, Vincent Capaldi, Jacob Collen and Emerson M. Wickwire

Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward pp. 787-802

Sergio Torres-Rueda, Fern Terris-Prestholt, Mitzy Gafos, Pitchaya Peach Indravudh, Rebecca Giddings, Fiammetta Bozzani, Matthew Quaife, Lusine Ghazaryan, Carlyn Mann, Connie Osborne, Matthew Kavanagh, Peter Godfrey-Faussett, Graham Medley and Shelly Malhotra

Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review pp. 803-818

Gillian R. Currie, Brittany Gerber, Diane Lorenzetti, Karen MacDonald, Susanne M. Benseler, Francois P. Bernier, Kym M. Boycott, K. Vanessa Carias, Bettina Hamelin, Robin Z. Hayeems, Claire LeBlanc, Marinka Twilt, Gijs Rooijen, Durhane Wong-Rieger, Rae S. M. Yeung and Deborah A. Marshall

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States pp. 819-830

Mickaël Hiligsmann, Stuart S. Silverman, Andrea J. Singer, Leny Pearman, Jake Mathew, Yamei Wang, John Caminis and Jean-Yves Reginster

Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions pp. 831-841

James Love-Koh, Paul Schneider, Simon McNamara, Tim Doran and Nils Gutacker

Volume 41, issue 6, 2023

The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice pp. 607-617

Bram Wouterse, Pieter Baal, Matthijs Versteegh and Werner Brouwer

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations pp. 619-632

Thomas Michael Otten, Sabine E. Grimm, Bram Ramaekers and Manuela A. Joore

Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review pp. 633-650

Olena Mandrik, Anne I. Hahn, James W. F. Catto, Ann G. Zauber, Marcus Cumberbatch and James Chilcott

Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review pp. 651-673

Yared Belete Belay, Lidia Engel, Yong Yi Lee, Ngoc Le and Cathrine Mihalopoulos

Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review pp. 675-692

Sean P. Gavan, Stuart J. Wright, Fiona Thistlethwaite and Katherine Payne

Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models pp. 693-707

Rebecca Giddings, Pitchaya Indravudh, Graham F. Medley, Fiammetta Bozzani, Mitzy Gafos, Shelly Malhotra, Fern Terris-Prestholt, Sergio Torres-Rueda and Matthew Quaife

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA pp. 709-718

Prajakta P. Masurkar, Haluk Damgacioglu, Ashish A. Deshmukh and Meghana V. Trivedi

Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031 pp. 719-732

Dina Abushanab, Clara Marquina, Jedidiah I. Morton, Daoud Al-Badriyeh, Melanie Lloyd, Dianna J. Magliano, Danny Liew and Zanfina Ademi

Volume 41, issue 5, 2023

Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review pp. 467-480

Fiammetta M. Bozzani, Fern Terris-Prestholt, Matthew Quaife, Mitzy Gafos, Pitchaya P. Indravudh, Rebecca Giddings, Graham F. Medley, Shelly Malhotra and Sergio Torres-Rueda

Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella pp. 481-497

Kris Doggen, Albert Jan van Hoek and Jeroen Luyten

Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review pp. 499-527

Emily R. Strouphauer, Olivia J. Morris, Keaton J. Soileau, Andrew D. Wiese, Troy Quast, Wayne K. Goodman, Sameer A. Sheth, Katharine D. Wojcik, Andrew G. Guzick and Eric A. Storch

HTA Barriers for Conditional Approval Drugs pp. 529-545

Mackenzie Mills

Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK pp. 547-559

Junwen Zhou, Runguo Wu, Claire Williams, Jonathan Emberson, Christina Reith, Anthony Keech, John Robson, Kenneth Wilkinson, Jane Armitage, Alastair Gray, John Simes, Colin Baigent and Borislava Mihaylova

How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes pp. 561-572

Valeska Hofbauer-Milan, Stefan Fetzer and Christian Hagist

The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight) pp. 573-587

Jacqueline Roseleur, David A. Gonzalez-Chica, Gillian Harvey, Nigel P. Stocks and Jonathan Karnon

Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan pp. 589-604

Taku Kobayashi, Masato Hoshi, Akira Yuasa, Shoko Arai, Mitsunobu Ikeda, Hiroyuki Matsuda, Seok-Won Kim and Toshifumi Hibi

Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US pp. 605-605

Hardik Goswami, Adnan Alsumali, Yiling Jiang, Matthias Schindler, Elizabeth R. Duke, Joshua Cohen, Andrew Briggs and Amy Puenpatom

Volume 41, issue 4, 2023

Modelling the Cost-Effectiveness of Diagnostic Tests pp. 339-351

Tristan Snowsill

Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 353-361

Mohamed N. M. T. Al Khayat, Nigel Armstrong, Jeremy Howick, Susan O’Meara, Pawel Posadzki, Steve Ryder, Charlotte Ahmadu, Stefan R. A. Konings, Maarten J. Postma, Steven Duffy, Robert F. Wolff and Antoinette D. I. Asselt

Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review pp. 363-391

Nannan Li, Charlotte Beaudart, Jane A. Cauley, Steven W. Ing, Nancy E. Lane, Jean-Yves Reginster, Stuart Silverman, Andrea J. Singer and Mickaël Hiligsmann

Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review pp. 393-393

Nannan Li, Charlotte Beaudart, Jane A. Cauley, Steven W. Ing, Nancy E. Lane, Jean‑Yves Reginster, Stuart Silverman, Andrea J. Singer and Mickaël Hiligsmann

Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations pp. 395-411

Carina M. Behr, Martijn J. Oude Wolcherink, Maarten J. IJzerman, Rozemarijn Vliegenthart and Hendrik Koffijberg

Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario pp. 413-425

John J. Kim, Wasem Alsabbagh and William W. L. Wong

The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia pp. 427-438

Richard Norman, Brendan Mulhern, Emily Lancsar, Paula Lorgelly, Julie Ratcliffe, Deborah Street and Rosalie Viney

Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study pp. 439-455

Mengmeng Zhang, Yun Bao, Yi Yang, Melissa Kimber, Mitchell Levine and Feng Xie

Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis pp. 457-466

Praveen Thokala, Pann Ei Hnynn Si, Monica Hernandez Alava, Alessandro Sasso, Thilo Schaufler, Marco Soro and James Fotheringham

Volume 41, issue 3, 2023

Living Health Technology Assessment: Issues, Challenges and Opportunities pp. 227-237

Praveen Thokala, Tushar Srivastava, Robert Smith, Shijie Ren, Melanie D. Whittington, Jamie Elvidge, Ruth Wong and Lesley Uttley

Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 239-251

Antoinette D. I. Asselt, Nigel Armstrong, Merel Kimman, Andrea Peeters, Kevin McDermott, Lisa Stirk, Charlotte Ahmadu, Tim M. Govers, Frank Hoentjen, Manuela A. Joore and Sabine E. Grimm

Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review pp. 253-273

Marie-Hélène Blanchet Zumofen, Jeff Frimpter and Svenn Alexander Hansen

Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review pp. 275-293

Erik Landfeldt, Sophia Abner, Astrid Pechmann, Thomas Sejersen, Hugh J. McMillan, Hanns Lochmüller and Janbernd Kirschner

Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment pp. 295-306

Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang and Yun Lu

Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy pp. 307-319

Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen and Nai-Jung Chiang

Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? pp. 321-327

R. Brett McQueen, Kelly E. Anderson, Joseph F. Levy and Josh J. Carlson

The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned pp. 329-338

Sahar Al Shabasy, Bram Roudijk, Maggie Abbassi, Aureliano Finch, Elly Stolk and Samar Farid

Volume 41, issue 2, 2023

Best Practices: A Collection of Systematic Critical Reviews of Modeling Approaches in Specific Disease Areas pp. 119-121

J. Jaime Caro

How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe pp. 123-138

Tuba Saygın Avşar, Xiaozhe Yang and Paula Lorgelly

The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies pp. 139-153

Claire Lin, Xiaoyu Zhang and Huajie Jin

Psychometric Properties of Generic Preference-Weighted Measures for Children and Adolescents: A Systematic Review pp. 155-174

Rachel Lee-Yin Tan, Sonia Zhi Yi Soh, Le Ann Chen, Michael Herdman and Nan Luo

Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement pp. 175-186

Amy Gye, Stephen Goodall and Richard Abreu Lourenco

Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L pp. 187-198

Mona Aghdaee, Yuanyuan Gu, Kompal Sinha, Bonny Parkinson, Rajan Sharma and Henry Cutler

Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study pp. 199-207

Monica Hernandez Alava, Steve Pudney and Allan Wailoo

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy pp. 209-225

Carla Rognoni, Camilla Falivena, Francesco Costa and Patrizio Armeni

Volume 41, issue 1, 2023

Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial pp. 5-19

Nathan Green, Felicity Lamrock, Nichola Naylor, Jack Williams and Andrew Briggs

Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses pp. 21-32

Nichola R. Naylor, Jack Williams, Nathan Green, Felicity Lamrock and Andrew Briggs

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 33-42

Ben Wijnen, Willem Witlox, Robert Wolff, Debra Fayter, Bram Ramaekers, Thomas Otten, Steve Ryder, Pawel Posadzki, Gill Worthy, Lisa Stirk, Nigel Armstrong, Jos Kleijnen and Manuela Joore

Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments pp. 43-57

Shan Jiang, Ru Ren, Yuanyuan Gu, Varinder Jeet, Ping Liu and Shunping Li

The Costs of Dementia in Europe: An Updated Review and Meta-analysis pp. 59-75

Linus Jönsson, Ashley Tate, Oskar Frisell and Anders Wimo

Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures pp. 77-91

Siobhan Botwright, Ei Mon Win, Nattiya Kapol, Sirikanlaya Benjawan and Yot Teerawattananon

Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis pp. 93-105

Corneliu Bolbocean, Sylvia Pal, Stef Buuren, Peter J. Anderson, Peter Bartmann, Nicole Baumann, Jeanie L. Y. Cheong, Brian A. Darlow, Lex W. Doyle, Kari Anne I. Evensen, John Horwood, Marit S. Indredavik, Samantha Johnson, Neil Marlow, Marina Mendonça, Yanyan Ni, Dieter Wolke, Lianne Woodward, Erik Verrips and Stavros Petrou

Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service pp. 107-117

Pierluigi Russo, Matteo Zanuzzi, Angelica Carletto, Annalisa Sammarco, Federica Romano and Andrea Manca